{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:05Z","timestamp":1775872265304,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.7759\/cureus.103244","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:21:57Z","timestamp":1770621717000},"source":"Crossref","is-referenced-by-count":1,"title":["Treating Acute Toxo-Metabolic Encephalopathy With Continuous Renal Replacement Therapy: A Case Report of Ifosfamide Neurotoxicity"],"prefix":"10.7759","author":[{"given":"Bilal Shahzad Azam","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumayya","family":"Din Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.8.556","article-title":"Ifosfamide","volume":"80","author":"Zalupski M","year":"1988","unstructured":"Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst. 1988, 80:556-66. 10.1093\/jnci\/80.8.556","journal-title":"J Natl Cancer Inst"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000158439.02724.5a","article-title":"Evaluating risk factors for the development of ifosfamide encephalopathy","volume":"28","author":"David KA","year":"2005","unstructured":"David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005, 28:277-80. 10.1097\/01.coc.0000158439.02724.5a","journal-title":"Am J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2011.43.4.260","article-title":"Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases","volume":"43","author":"Shin YJ","year":"2011","unstructured":"Shin YJ, Kim JY, Moon JW, et al.. Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases. Cancer Res Treat. 2011, 43:260-3. 10.4143\/crt.2011.43.4.260","journal-title":"Cancer Res Treat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","article-title":"Ifosfamide","author":"Gangireddy M","year":"20259","unstructured":"Gangireddy M, Patel P, Nookala V. Ifosfamide. StatPearls, Treasure Island (FL); 20259."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140010-00004","article-title":"Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites","volume":"40","author":"Kerbusch T","year":"2001","unstructured":"Kerbusch T, de Kraker J, Keizer HJ, et al.. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001, 40:41-62. 10.2165\/00003088-200140010-00004","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs JJ","year":"2012","unstructured":"Griggs JJ, Mangu PB, Anderson H, et al.. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012, 30:1553-61. 10.1200\/JCO.2011.39.9436","journal-title":"J Clin Oncol"},{"key":"ref8","article-title":"Metabolic encephalopathies","author":"Chen R","unstructured":"Chen R, Young GB. Metabolic encephalopathies. Bailli\u00e8re\u2019s Clinical Neurology. Bolton CF, Young GB (ed): Bailli\u00e8re Tindall, London; 577."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000073351","article-title":"Side effects of ifosfamide","volume":"65 Suppl 2","author":"Klastersky J","year":"2003","unstructured":"Klastersky J. Side effects of ifosfamide. Oncology. 2003, 65 Suppl 2:7-10. 10.1159\/000073351","journal-title":"Oncology"},{"key":"ref10","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). (2003). Accessed: February 9, 2026: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v3.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(86)90368-8","article-title":"Prediction of ifosfamide\/mesna associated encephalopathy","volume":"22","author":"Meanwell CA","year":"1986","unstructured":"Meanwell CA, Blake AE, Kelly KA, et al.. Prediction of ifosfamide\/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986, 22:815. 10.1016\/0277-5379(86)90368-8","journal-title":"Eur J Cancer Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000527","article-title":"The use of continuous veno-venous hemodiafiltration in the management of ifosfamide-induced encephalopathy: a case report","volume":"38","author":"Yeo KK","year":"2016","unstructured":"Yeo KK, HaDuong JH. The use of continuous veno-venous hemodiafiltration in the management of ifosfamide-induced encephalopathy: a case report. J Pediatr Hematol Oncol. 2016, 38:489-90. 10.1097\/MPH.0000000000000527","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10047-013-0733-1","article-title":"Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury","volume":"17","author":"Nishimura H","year":"2014","unstructured":"Nishimura H, Enokida H, Nagano S, et al.. Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. J Artif Organs. 2014, 17:110-3. 10.1007\/s10047-013-0733-1","journal-title":"J Artif Organs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212459285","article-title":"Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report","volume":"19","author":"Cherry MA","year":"2013","unstructured":"Cherry MA, Bhardwaj H, Hopps S, et al.. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. J Oncol Pharm Pract. 2013, 19:261-4. 10.1177\/1078155212459285","journal-title":"J Oncol Pharm Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.5.1088","article-title":"Haemoperfusion combined with haemodialysis in ifosfamide intoxication","volume":"16","author":"Fiedler R","year":"2001","unstructured":"Fiedler R, Baumann F, Deschler B, Osten B. Haemoperfusion combined with haemodialysis in ifosfamide intoxication. Nephrol Dial Transplant. 2001, 16:1088-9. 10.1093\/ndt\/16.5.1088","journal-title":"Nephrol Dial Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2006.11.003","article-title":"Ifosfamide encephalopathy","volume":"19","author":"Ajithkumar T","year":"2007","unstructured":"Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007, 19:108-14. 10.1016\/j.clon.2006.11.003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050720","article-title":"Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor","volume":"41","author":"Carlson L","year":"1998","unstructured":"Carlson L, Goren MP, Bush DA, et al.. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor. Cancer Chemother Pharmacol. 1998, 41:140-6. 10.1007\/s002800050720","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G114","article-title":"Methylene blue for management of Ifosfamide-induced encephalopathy","volume":"40","author":"Patel PN","year":"2006","unstructured":"Patel PN. Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother. 2006, 40:299-303. 10.1345\/aph.1G114","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456461-treating-acute-toxo-metabolic-encephalopathy-with-continuous-renal-replacement-therapy-a-case-report-of-ifosfamide-neurotoxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:22:00Z","timestamp":1770621720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456461-treating-acute-toxo-metabolic-encephalopathy-with-continuous-renal-replacement-therapy-a-case-report-of-ifosfamide-neurotoxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.103244","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,8]]}}}